FGF21 Hormone Protects Against High Blood Pressure and Vascular Damage in Mice
New research shows FGF21 hormone prevents hypertension by activating protective cardiovascular pathways in mouse models.
Résumé
Scientists discovered that FGF21, a hormone naturally produced by the liver, can prevent high blood pressure and blood vessel damage in mice. The study found that FGF21 works by activating the ACE2/Angiotensin-(1-7) pathway, which counteracts harmful effects of angiotensin II - a compound that typically raises blood pressure and damages blood vessels. When researchers gave mice angiotensin II to induce hypertension, those also receiving FGF21 treatment maintained healthier blood pressure levels and better vascular function. This protective effect occurred through FGF21's ability to boost ACE2 enzyme activity, which converts harmful angiotensin II into beneficial angiotensin-(1-7). The findings suggest FGF21 could be a promising therapeutic target for preventing cardiovascular disease and hypertension.
Résumé détaillé
Cardiovascular disease remains the leading cause of death globally, making new protective mechanisms crucial for longevity research. This study investigated whether FGF21, a metabolic hormone known for its anti-aging properties, could protect against hypertension and vascular dysfunction.
Researchers used mouse models to test FGF21's effects against angiotensin II-induced hypertension. Angiotensin II is a potent vasoconstrictor that raises blood pressure and damages blood vessels. The team administered FGF21 treatment alongside angiotensin II to determine if the hormone could prevent these harmful effects.
The results showed FGF21 successfully prevented both hypertension and vascular dysfunction in treated mice. The protective mechanism involved activation of the ACE2/Angiotensin-(1-7) axis - a beneficial pathway that counteracts the renin-angiotensin system's harmful effects. FGF21 increased ACE2 enzyme activity, which converts damaging angiotensin II into protective angiotensin-(1-7), promoting vasodilation and reducing inflammation.
These findings have significant implications for cardiovascular health and longevity. FGF21 levels naturally decline with age, potentially contributing to increased cardiovascular risk in older adults. The study suggests that maintaining or boosting FGF21 levels could protect against age-related hypertension and vascular damage. This adds to growing evidence that FGF21 is a key longevity hormone with multiple protective effects. However, the research was conducted in mice, and human studies are needed to confirm these cardiovascular benefits and determine optimal therapeutic approaches.
Principales conclusions
- FGF21 hormone prevents angiotensin II-induced high blood pressure in mouse models
- Treatment activates protective ACE2/Angiotensin-(1-7) pathway in blood vessels
- FGF21 increases ACE2 enzyme activity, converting harmful compounds to beneficial ones
- Protective effects include improved vascular function and reduced cardiovascular damage
Méthodologie
Mouse model study using angiotensin II infusion to induce hypertension, with FGF21 treatment groups compared to controls. Researchers measured blood pressure, vascular function, and ACE2/Angiotensin-(1-7) pathway activity. Study design included appropriate control groups to isolate FGF21's specific effects.
Limites de l'étude
Study conducted only in mice, requiring human clinical trials to confirm cardiovascular benefits. Long-term safety and optimal dosing of FGF21 interventions remain unknown. The specific mechanisms translating to human physiology need validation.
Ce résumé vous a plu ?
Recevez les dernières recherches sur la longévité dans votre boîte de réception chaque semaine.
Saisissez votre e-mail pour vous abonner :